Clinical Trial Update: Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I) [Phase 2]

View source ↗

Summary

Phase 2 ADME study reporting absorption and systemic exposure of tavaborole (AN2690) in patients with moderate to severe onychomycosis; trial status is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Onychomycosis

Drugs mentioned

• Tavaborole (Tavaborole)

Snippet

Sponsor: Pfizer | Conditions: Onychomycosis | Phase 2 | Status: COMPLETED